JP2010520884A - 鉄障害を処置するために有用な三環系化合物 - Google Patents

鉄障害を処置するために有用な三環系化合物 Download PDF

Info

Publication number
JP2010520884A
JP2010520884A JP2009552912A JP2009552912A JP2010520884A JP 2010520884 A JP2010520884 A JP 2010520884A JP 2009552912 A JP2009552912 A JP 2009552912A JP 2009552912 A JP2009552912 A JP 2009552912A JP 2010520884 A JP2010520884 A JP 2010520884A
Authority
JP
Japan
Prior art keywords
optionally substituted
independently
alkyl
hydrogen
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009552912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520884A5 (enExample
Inventor
ミカエル チャフィーブ，
ナガスリー チャッカ，
ジャン−ジャック シャデュー，
チアンミン フー，
ラジェンダー カンボイ，
ヴィシュヌムルティ コドュムル，
ジョナサン ランギル，
シーフェン リュー，
チアンユー サン，
セルゲイ スヴィリドフ，
チャイホイ チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of JP2010520884A publication Critical patent/JP2010520884A/ja
Publication of JP2010520884A5 publication Critical patent/JP2010520884A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/08—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing three- or four-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009552912A 2007-03-07 2008-03-07 鉄障害を処置するために有用な三環系化合物 Withdrawn JP2010520884A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89358507P 2007-03-07 2007-03-07
PCT/US2008/056250 WO2008109840A1 (en) 2007-03-07 2008-03-07 Tricyclic compounds useful in treating iron disorders

Publications (2)

Publication Number Publication Date
JP2010520884A true JP2010520884A (ja) 2010-06-17
JP2010520884A5 JP2010520884A5 (enExample) 2012-07-05

Family

ID=39512833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552912A Withdrawn JP2010520884A (ja) 2007-03-07 2008-03-07 鉄障害を処置するために有用な三環系化合物

Country Status (13)

Country Link
US (1) US20090069408A1 (enExample)
EP (1) EP2061755A1 (enExample)
JP (1) JP2010520884A (enExample)
CN (1) CN101616892A (enExample)
AR (1) AR065628A1 (enExample)
AU (1) AU2008222666A1 (enExample)
BR (1) BRPI0808043A2 (enExample)
CA (1) CA2678895A1 (enExample)
CL (1) CL2008000666A1 (enExample)
MX (1) MX2009009466A (enExample)
RU (1) RU2009136996A (enExample)
TW (1) TW200845961A (enExample)
WO (1) WO2008109840A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023177660A (ja) * 2022-06-02 2023-12-14 旭化成株式会社 ルテニウム錯体の製造方法、並びにルテニウム錯体及びこれを用いたジアミンの製造方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2688547A1 (en) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals, Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
AR077892A1 (es) 2009-08-20 2011-09-28 Vifor Int Ag Quinolinas antagonistas de la hepcidina
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
TW201113274A (en) 2009-09-07 2011-04-16 Vifor Int Ag Novel ethanediamine hepcidine antagonists
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
JP6810988B2 (ja) 2015-10-23 2021-01-13 ヴィフォール （インターナショナル） アクチェンゲゼルシャフトＶｉｆｏｒ （Ｉｎｔｅｒｎａｔｉｏｎａｌ） ＡＧ 新規なフェロポーチン阻害剤
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
CN114163417B (zh) * 2021-12-06 2023-08-04 郑州海阔光电材料有限公司 一种3-溴硫芴的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
US6310243B1 (en) * 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
US6080587A (en) * 1998-01-23 2000-06-27 Eli Lilly And Company Method for preparing and selecting pharmaceutically useful sulfur-bridged bi- and triaromatic ring compounds from a structurally diverse universal library
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US20060269498A1 (en) * 2005-05-17 2006-11-30 Gerard Malle Hair shaping composition comprising at least one polyguanidine other than hydroxide
CA2688547A1 (en) * 2007-06-05 2008-12-11 Xenon Pharmaceuticals, Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023177660A (ja) * 2022-06-02 2023-12-14 旭化成株式会社 ルテニウム錯体の製造方法、並びにルテニウム錯体及びこれを用いたジアミンの製造方法

Also Published As

Publication number Publication date
AR065628A1 (es) 2009-06-17
AU2008222666A1 (en) 2008-09-12
EP2061755A1 (en) 2009-05-27
RU2009136996A (ru) 2011-04-20
WO2008109840A1 (en) 2008-09-12
CL2008000666A1 (es) 2008-06-13
BRPI0808043A2 (pt) 2014-06-24
US20090069408A1 (en) 2009-03-12
CN101616892A (zh) 2009-12-30
MX2009009466A (es) 2009-09-15
TW200845961A (en) 2008-12-01
CA2678895A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
JP2010520884A (ja) 鉄障害を処置するために有用な三環系化合物
US20080234327A1 (en) Dihydroindazole compounds useful in treating iron disorders
US20100240713A1 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
JP2010522197A (ja) 鉄障害を治療するのに有用なビアリール化合物およびヘテロビアリール化合物
JP2021107425A (ja) 自己免疫障害および炎症性障害の処置において有用な置換型１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドル−３−イル）酢酸誘導体
WO2008121861A2 (en) Pyrazole and pyrrole compounds useful in treating iron disorders
JP3895404B2 (ja) カルコン誘導体及びこれを含有する医薬
CN113518776B (zh) 苯并噻吩类化合物及其制备方法和用途
US20070249661A1 (en) Compounds for inflammation and immune-related uses
JPH057386B2 (enExample)
CA2775309A1 (en) A phenol derivative and its pharmaceutical use
JP2005514452A (ja) フェニル（アルキル）カルボン酸誘導体およびジオニックフェニルアルキル複素環誘導体およびそれらの血清グルコースおよび／または血清脂質低下活性を有する医薬としての使用
KR20150002713A (ko) 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체
KR20090025367A (ko) 신규 6-5계 이환식 복소환 유도체 및 그 의약용도
AU2021411658B2 (en) 2-pyridone derivative, and preparation method therefor and pharmaceutical application thereof
US20180194710A1 (en) Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof
Guo et al. Design and optimization of 2, 3-dihydrobenzo [b][1, 4] dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles
JP2016518449A (ja) インドール製剤を調製するためのプロセスおよび中間体
JPH09176165A (ja) イミダゾ［１，２−ａ］ピリジン誘導体、その製法およびその用途
CN119019331A (zh) 一种三环类衍生物及其应用
HK40018543B (zh) 芳香族化合物及其药物组合物和用途
JP2009511422A (ja) Ａｍｐａ受容体増強剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110224

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20120629

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20120703